Choice of the treating methods of neovascular age-related macular degeneration
10.3760/cma.j.issn.2095-0160.2012.11.001
- VernacularTitle:湿性年龄相关性黄斑变性治疗方法的新选择
- Author:
Jun-jun, ZHANG
;
Mei-xia, ZHANG
- Publication Type:Journal Article
- Keywords:
Age-related macular degeneration;
Choroidal neovascularization;
Targeted drug therapy;
Gene therapy;
Stem cell therapy
- From:
Chinese Journal of Experimental Ophthalmology
2012;(11):961-964
- CountryChina
- Language:Chinese
-
Abstract:
Neovascular age-related macular degeneration (AMD) is the main cause of vision loss in AMD patient.Now,the application of anti-vascular endothelial growth factor(VEGF) has become the preferred therapy for the treatment of neovascular AMD,and it has been proved to improve the visual acuity and reduce the blindness rate.But the formation of choroidal neovascularization (CNV) in AMD is a comprehensive and integrated pathological process.It is difficult to cure the CNV with only anti-VEGF drug for all the neovascular AMD patients.Therefore,the targeting drugs toward other signal pathway associated with CNV are being in different phases of clinical trials.Resent years,with the development of science and technology,small interference RNA(siRNA) and genome technology has been applied to treat neovascular AMD and show a potential prospect,and gene therapy and stem cell therapy are the most remarkable and predominant ways for AMD.Doubtlessly,these therapies offer novel choice for the management of neovascular AMD.
